

CLAIMS:

1. A peptide, in substantially isolated form, which substantially includes the amino-terminal amino acid sequence: ^{6,7}LQTPQPLLQVMMEPQGD-OH (SEQ ID 1);
- 5 MPQNFYKLPQM (SEQ ID 2); VLEMKFPPPPQETVT (SEQ ID 3); LKPFPKLKVEVFFFP (SEQ ID 4); SEQP (SEQ ID 5); DKE (SEQ ID 6); DPPPPQS (SEQ ID 7); LNF (SEQ ID 8); VLPPNVG (SEQ ID 9); KYKLQPE (SEQ ID 10); SEEMP (SEQ ID 11); DSQPPV (SEQ ID 12); FPPPK (SEQ ID 13); VMEV (SEQ ID 14); DLEMPVLPVEPFPFV (SEQ ID 15); LFFFLPVVNVLP (SEQ ID 16); MQPPPLP (SEQ ID 17);
- 10 DQPPDVEKPDLPFQVQS (SEQ ID 18); VYPFTGPIPN (SEQ ID 19); SLPQNILPL (SEQ ID 20); TQTPVVPPF (SEQ ID 21); LQPEIMGVPKVKETMVPK (SEQ ID 22); HKEMPFKYPVEPFTESQ (SEQ ID 23); SLTLTDVEKLHLPLPLVQ (SEQ ID 24); SWMHQPP (SEQ ID 25); QLPPTVMFP (SEQ ID 26); MHQPPQPLPPTVMFP (SEQ ID 27); PQSVLS (SEQ ID 28); LSQPKVLPVPQKAVPQRDMPIQ (SEQ ID 29); AFLLYQE
- 15 (SEQ ID 30); FLLYQEPVLGPVR (SEQ ID 31); RGPFPILV (SEQ ID 32); ATFNRYQDDHGEEILKSL (SEQ ID 33).
2. A peptide, in substantially isolated form, which substantially includes the amino acid sequence: LQTPQPLLQVMMEPQGD (SEQ ID 1); MPQNFYKLPQM (SEQ ID 2);
- 20 VLEMKFPPPPQETVT (SEQ ID 3); LKPFPKLKVEVFFFP (SEQ ID 4); DPPPPQS (SEQ ID 7); VLPPNVG (SEQ ID 9); KYKLQPE (SEQ ID 10); DSQPPV (SEQ ID 12); DLEMPVLPVEPFPFV (SEQ ID 15); LFFFLPVVNVLP (SEQ ID 16); MQPPPLP (SEQ ID 17); DQPPDVEKPDLPFQVQS (SEQ ID 18).
- 25 3. A peptide, in substantially isolated form, which substantially entirely consists of the amino acid sequence: LQTPQPLLQVMMEPQGD (SEQ ID 1); MPQNFYKLPQM (SEQ ID 2); VLEMKFPPPPQETVT (SEQ ID 3); LKPFPKLKVEVFFFP (SEQ ID 4); SEQP (SEQ ID 5); DKE (SEQ ID 6); DPPPPQS (SEQ ID 7); LNF (SEQ ID 8); VLPPNVG (SEQ ID 9); KYKLQPE (SEQ ID 10); SEEMP (SEQ ID 11); DSQPPV (SEQ ID 12); FPPPK
- 30 (SEQ ID 13); VMEV (SEQ ID 14); DLEMPVLPVEPFPFV (SEQ ID 15); LFFFLPVVNVLP (SEQ ID 16); MQPPPLP (SEQ ID 17); DQPPDVEKPDLPFQVQS

(SEQ ID 18); VYPFTGPIPN (SEQ ID 19); SLPQNILPL (SEQ ID 20); TQTPVVPPF (SEQ ID 21); LQPEIMGVPKVKETMVPK (SEQ ID 22); HKEMPFKYPVEPFTESQ (SEQ ID 23); SLTLTDVEKLHLPLPLVQ (SEQ ID 24); SWMHQPP (SEQ ID 25); QPLPPTVMFP (SEQ ID 26); MHQPPQPLPPTVMFP (SEQ ID 27); PQSVLS (SEQ ID 28);
 5 LSQPKVLPVPQKAVPQRDMPIQ (SEQ ID 29); AFLLYQE (SEQ ID 30); FLLYQEPVLGPVR (SEQ ID 31); RGPFPILV (SEQ ID 32); ATFNRYQDDHGEEILKSL (SEQ ID 33).

Sup
 10 4. A peptide according to claim 1, 2 or 3, when obtained by a synthetic process.

5. A peptide obtained by a synthetic process, which substantially includes the amino-terminal amino acid sequence: LQTPQPLLQVMMEPQGD (SEQ ID 1); MPQNFYKLPQM (SEQ ID 2); VLEMKFPPPPQETVT (SEQ ID 3); LKPFKPKLKEVFFPF (SEQ ID 4); SEQP (SEQ ID 5); DKE (SEQ ID 6); DPPPPQS (SEQ ID 7); LNF (SEQ ID
 15 8); VLPPNVG (SEQ ID 9); KYKLQPE (SEQ ID 10); SEEMP (SEQ ID 11); DSQPPV (SEQ ID 12); FPPPK (SEQ ID 13); VMEV (SEQ ID 14); DLEMPVLPVEPFPFV (SEQ ID 15); LFFFLPVNVLP (SEQ ID 16); MQPPPLP (SEQ ID 17); DQPPDVEKPDLPFQVQS (SEQ ID 18); VYPFTGPIPN (SEQ ID 19); SLPQNILPL (SEQ ID 20); TQTPVVPPF (SEQ ID 21); LQPEIMGVPKVKETMVPK (SEQ ID 22);
 20 HKEMPFKYPVEPFTESQ (SEQ ID 23); SLTLTDVEKLHLPLPLVQ (SEQ ID 24); SWMHQPP (SEQ ID 25); QPLPPTVMFP (SEQ ID 26); MHQPPQPLPPTVMFP (SEQ ID 27); PQSVLS (SEQ ID 28); LSQPKVLPVPQKAVPQRDMPIQ (SEQ ID 29); AFLLYQE (SEQ ID 30); FLLYQEPVLGPVR (SEQ ID 31); RGPFPILV (SEQ ID 32); ATFNRYQDDHGEEILKSL (SEQ ID 33).

25

6. A peptide obtained by a synthetic process, which substantially includes the amino acid sequence: LQTPQPLLQVMMEPQGD (SEQ ID 1); MPQNFYKLPQM (SEQ ID 2); VLEMKFPPPPQETVT (SEQ ID 3); LKPFKPKLKEVFFPF (SEQ ID 4); DPPPPQS (SEQ ID 7); VLPPNVG (SEQ ID 9); KYKLQPE (SEQ ID 10); DSQPPV (SEQ ID 12);
 30 DLEMPVLPVEPFPFV (SEQ ID 15); LFFFLPVNVLP (SEQ ID 16); MQPPPLP (SEQ ID 17); DQPPDVEKPDLPFQVQS (SEQ ID 18).

-27-

7. A peptide obtained by a synthetic process, which substantially entirely consists of the amino acid sequence: LQTPQPLLQVMMEPQGD (SEQ ID 1); MPQNFYKLPQM (SEQ ID 2); VLEMKFPPPPQETVT (SEQ ID 3); LKPFKPKLKVEVFPFP (SEQ ID 4); SEQP (SEQ ID 5); DKE (SEQ ID 6); DPPPPQS (SEQ ID 7); LNF (SEQ ID 8); VLPPNVG (SEQ ID 9); KYKLQPE (SEQ ID 10); SEEMP (SEQ ID 11); DSQPPV (SEQ ID 12); FPPPK (SEQ ID 13); VMEV (SEQ ID 14); DLEMPVLPVEPFPFV (SEQ ID 15); LFFFLPVVNVLP (SEQ ID 16); MQPPPLP (SEQ ID 17); DQPPDVEKPDLPFQVQS (SEQ ID 18); VYPFTGPIPN (SEQ ID 19); SLPQNILPL (SEQ ID 20); TQTPVVVPPF (SEQ ID 21); LQPEIMGVPKVKETMVPK (SEQ ID 22); HKEMPFKYPVEPFTESQ (SEQ ID 23); SLTLTDVEKLHLPLPLVQ (SEQ ID 24); SWMHQPP (SEQ ID 25); QPLPPTVMFP (SEQ ID 26); MHQPPQPLPPTVMFP (SEQ ID 27); PQSVLS (SEQ ID 28); LSQPKVLPVPQKAVPQRDMPIQ (SEQ ID 29); AFLLYQE (SEQ ID 30); FLLYQEPVLGPVR (SEQ ID 31); RGPFPILV (SEQ ID 32); ATFNRYQDDHGEEILKSL (SEQ ID 33).

15

8. A peptide comprising: NH_2 -(Ac)CLQTPQPLLQVMMEPQGD-OH (SEQ ID 34); NH_2 -(Ac)CMPQNFYKLPQM-OH (SEQ ID 35); NH_2 -(Ac)CVLEMKFPPPPQETVT-OH (SEQ ID 36); NH_2 -(Ac)CLKPFKPKLKVEVFPFP-OH (SEQ ID 37); NH_2 -SEQPGGGC-OH (SEQ ID 38); NH_2 -(Ac)CGVLPPNVG-OH (SEQ ID 39); NH_2 -(Ac)CGGGKYKLQE-OH (SEQ ID 40); NH_2 -(Ac)CGGGSEEMP(amide)-OH (SEQ ID 41); NH_2 -(Ac)CGGGDSQPPV-OH (SEQ ID 42); NH_2 -CFPPPKGGGC-OH (SEQ ID 43); NH_2 -(Ac)CGGGVMEV-OH (SEQ ID 44); NH_2 -(Ac)CDLEMPVLPVEPFPFV-OH (SEQ ID 45); NH_2 -(Ac)CLFFFLPVVNVLP-OH (SEQ ID 46); NH_2 -(Ac)CMQPPPLP-OH (SEQ ID 47); NH_2 -(Ac)CDQPPDVEKPDLPFQVQS-OH (SEQ ID 48); NH_2 -(Ac)CGAFLLYQE-OH (SEQ ID 49); NH_2 -(Ac)CATFNRYQDDHGEEILKSL-OH (SEQ ID 50).

25

9. A peptide according to any preceding claim, for use as a medicament.

10. A peptide according to claim 9, for use in the treatment of chronic disorders of the central nervous system.

30

11. A peptide according to claim 10, for use in the treatment of neurological disorders and/or mental disorders.

12. A peptide according to claim 9, for use in the treatment of dementia and/or
5 neurodegenerative diseases.

13. A peptide according to claim 9, for use in the treatment of Alzheimer's disease and/or motor neurone disease.

10 14. A peptide according to claim 9, for use in the treatment of psychosis and/or neurosis.

15. A peptide according to claim 9, for use in the treatment of chronic disorders of the immune system.

15

16. A peptide according to claim 9, for use in the treatment of diseases with a bacterial and viral aetiology, and/or for use in the treatment of acquired immunological deficiencies.

20 17. A peptide according to claim 9, for use in the treatment of chronic bacterial and/or viral infections.

18. A peptide according to claim 9, for use in the treatment of diseases characterised by the presence of β -amyloid plaque.

25

Sub a2 19. The use of a peptide according to any one of claims 1 to 8, in the manufacture of a medicament for the treatment of chronic disorders of the central nervous system.

20. The use of a peptide according to any one of claims 1 to 8 in the manufacture of
30 a medicament for the treatment of chronic disorders of the immune system.

21. A method of treating disorders of the central nervous system and/or of the immune system, comprising administering a therapeutically effective amount of a peptide according to any one of claims 1 to 8 to a patient.
- 5 22. A composition comprising a peptide according to any one of claims 1 to 8, in combination with a physiologically acceptable carrier.
23. A composition comprising two or more peptides according to any one of claims 1 to 8, in combination with a physiologically acceptable carrier.
- 10 24. A composition according to claim 22 or 23, in a form suitable for injection.
25. A composition according to claim 22 or 23, in a form suitable for absorption through the mucosa of the oral/nasopharyngeal cavity and/or in a form suitable for
15 absorption in the alimentary canal.
26. A composition according to claim 22 or 23, in the form of a tablet, lozenge, gel, patch or plaster.
- 20 27. A composition according to claim 22 or 23, in a form suitable for topical application.
28. The use of a peptide according to any one of claims 1 to 8 as a dietary supplement.
- 25 29. The use of a peptide according to any one of claims 1 to 8 as a dietary supplement for babies, small children, adults who have been subjected to chemotherapy and/or adults who have suffered from cachexia, or weight loss due to chronic disease.
- 30 30. A dietary supplement comprising an orally ingestible combination of a peptide according to any one of claims 1 to 8 combination with a physiologically acceptable

*Sub
27
cont*

carrier.

31. An antibody which binds to a peptide according to any one of claims 1 or 8.

5 32. An antibody obtainable by using a peptide according to any one of claims 1 to 8 as an antigen.

33. A peptide containing the amino acid sequence LQTPQPLLQVMMEPQGD; DPPPPQS; and/or LFFFLPVNVLP for use as an immunosuppressant.

10

34. A peptide containing the amino acid sequence LQTPQPLLQVMMEPQGD; DPPPPQS; and/or LFFFLPVNVLP for use in the treatment of autoimmune disorder.

15 35. A peptide containing the amino acid sequence LQTPQPLLQVMMEPQGD; DPPPPQS; and/or LFFFLPVNVLP for use in suppressing the rejection of transplanting organs.